Balyasny Asset Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Balyasny Asset Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-99,839	Closed	-$1.29M	–	1831
2019 Q1	$1.29M	Buy	+99,839	New	+$1.49M	0.01%	945
2018 Q3	–	Sell	-22,047	Closed	-$430K	–	2192
2018 Q2	$430K	Buy	22,047 +7,165	+48%	+$159K	﹤0.01%	1398
2018 Q1	$300K	Buy	+14,882	New	+$252K	﹤0.01%	1615
2017 Q2	–	Sell	-10,301	Closed	-$232K	–	1870
2017 Q1	$232K	Buy	+10,301	New	+$247K	﹤0.01%	1455
2016 Q2	–	Sell	-42,895	Closed	-$1M	–	1553
2016 Q1	$1M	Sell	42,895 -389,568	-90%	-$9.25M	0.01%	770
2015 Q4	$13.1M	Buy	+432,463	New	+$14M	0.09%	303

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's AMAG Position: Q2 2019 in Review

Balyasny Asset Management sold out of AMAG Pharmaceuticals (AMAG) in Q2 2019, closing a stake of 99,839 shares — an estimated $1.29M sold.

Balyasny Asset Management first reported a position in AMAG in Q4 2015 and held it in 6 quarters. The position peaked at $13.1M in Q4 2015. 170 funds tracked by Wall St. Rank hold AMAG as of Q2 2019.

Balyasny Asset Management reported no remaining AMAG Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Balyasny Asset Management sold 99,839 AMAG Pharmaceuticals shares in Q2 2019, an estimated $1.29M.
Balyasny Asset Management first reported a position in AMAG Pharmaceuticals in Q4 2015 and held it in 6 quarters.
Balyasny Asset Management's AMAG Pharmaceuticals position peaked at $13.1M in Q4 2015.
170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2019.

Based on Balyasny Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.